Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2020-07-27 Investor Presentation
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Opthea to Host Key Opinion Leader Symposium on wAMD and DME 2 pages 97.4KB
Investor Presentation Classification · 90% confidence The document is an ASX and media release dated 28 July 2020 from Opthea Limited announcing a Key Opinion Leader (KOL) symposium scheduled for August 6, 2020. The content focuses on the event details, clinical trial updates, and company information. It does not contain financial statements, earnings data, or detailed financial analysis. It is primarily an announcement of an upcoming investor-focused event with presentations and Q&A, which aligns with the definition of an Investor Presentation (IP). The document is not a full transcript, nor a report or regulatory filing. Therefore, the best classification is Investor Presentation (IP).
2020-07-27 English
Opthea Presents New Data from Ph 1b/2a DME Trial at ASRS 4 pages 294.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 27 July 2020 from Opthea Limited. It reports new clinical data from a Phase 1b/2a study of OPT-302 in diabetic macular edema presented at the 2020 Annual Meeting of the American Society of Retina Specialists. The content focuses on clinical trial results, safety profile, and future plans for Phase 3 trials. It is a press release announcing new data and upcoming events rather than a formal financial or regulatory report. There are no financial statements, regulatory certifications, or detailed management discussions typical of Annual Reports, Interim Reports, or Earnings Releases. It is not a call transcript, governance, or capital update document. The document is a company announcement of clinical data and event information, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and company update that does not fit other specific categories.
2020-07-26 English
Corporate Presentation of Ph1b/2a DME Trial Data (ASRS) 25 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial results for Opthea's Phase 1b/2a trial of OPT-302 combination therapy for persistent diabetic macular edema (DME). It includes clinical trial design, patient demographics, treatment regimens, safety and efficacy data, and scientific background on the drug and disease. The content is structured as a presentation with slides, disclaimers, and detailed clinical data, typical of an investor or scientific presentation rather than a formal regulatory filing or financial report. There is no indication that this is an official annual report, earnings release, audit report, or regulatory filing. The document is not a transcript of a call, nor a voting result or management change announcement. It is clearly a detailed investor presentation focusing on clinical trial data and company strategy related to the drug development. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-07-26 English
Initial Director's Interest Notice - LG 2 pages 150.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held directly and indirectly, and interests in contracts. The content is focused on reporting personal share transactions or holdings by a company director. The document length is 2186 characters, which is relatively short and specific to director interests. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2020-07-26 English
Opthea Appoints New Non-Executive Director 2 pages 98.6KB
Board/Management Information Classification · 95% confidence The document is an ASX and media release dated 24 July 2020 announcing the appointment of a new Non-Executive Director to the board of Opthea Limited. It contains biographical details about the new director, statements from the chairman and CEO, and background information about the company and its clinical trials. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The content focuses on a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 7136 characters, which is sufficient for a full announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2020-07-23 English
Opthea to Present OPT-302 DME Clinical Data at ASRS 2020 2 pages 123.8KB
Investor Presentation Classification · 90% confidence The document is an ASX and media release dated 23 July 2020 from Opthea Limited announcing that clinical trial results from the Phase 1b/2a study of OPT-302 in diabetic macular edema will be presented at the American Society of Retina Specialists 2020 Annual Meeting. It describes the upcoming presentation details, the nature of the clinical trial, and provides background on the company and its research. The document does not contain actual financial statements or detailed financial analysis, nor is it a transcript or a regulatory filing. It is an announcement about a clinical data presentation at a conference, which aligns with an Investor Presentation (IP) type, as it focuses on clinical data, company technology, and upcoming presentation to investors and specialists. The document length (8248 characters) and content indicate it is not a brief factsheet or a simple announcement of report publication. Therefore, the best fit is Investor Presentation (IP).
2020-07-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.